High preoperative HBsAg levels are associated with an increased risk for recurrence following curative resection among patients with HBV-related hepatocellular carcinoma.
Risankizumab produces rapid and sustained clinical remission and meaningful endoscopic outcomes through 52 weeks, with a favorable safety profile.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results